Company Description
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis.
In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases.
The company was incorporated in 2018 and is headquartered in Foster City, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jul 18, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 264 |
| CEO | Christopher Peetz |
Contact Details
Address: 950 Tower Lane, Suite 1050 Foster City, California 94404 United States | |
| Phone | 650 667 4085 |
| Website | mirumpharma.com |
Stock Details
| Ticker Symbol | MIRM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001759425 |
| CUSIP Number | 604749101 |
| ISIN Number | US6047491013 |
| Employer ID | 83-1281555 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christopher Peetz | Chief Executive Officer and Director |
| Peter Radovich M.B.A., Ph.D. | Chief Operating Officer and President |
| Eric H. Bjerkholt M.B.A. | Chief Financial Officer |
| Dr. Pamela Vig Ph.D. | Chief Scientific Officer |
| Andrew McKibben | Vice President of Investor Relations and Finance |
| Paul K. Ross | Chief Compliance Officer |
| Erin Campany | Senior Vice President of Human Resources |
| Lara Longpre MBA, MSC | Chief Development Officer |
| Vinita P. Kumar | Senior vice President of Quality |
| Dr. Jean-Luc Girardet Ph.D. | Senior Vice President of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 22, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Aug 7, 2024 | 10-Q | Quarterly Report |
| Aug 7, 2024 | 8-K | Current Report |
| Jul 10, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |